The debate supports treating this as a validation program before ranking it as a therapy. Perturbation should move a proximal molecular phenotype, then a disease-relevant phenotype, in that order.
Curated pathway from expert analysis
flowchart TD
A["FUS/TDP-43 Phase Separation<br/>Biophysical Determinants of Aggregation"]
B["Perturbation-First Validation<br/>Condensate Modulator Compounds Testing"]
C["Liquid vs Solid State Readout<br/>FRAP, Rheometry, Super-Resolution"]
D["Aggregation Reversal Confirmation<br/>Amyloid-Forming State Prevention"]
E["Motor Neuron Protection<br/>Phase Separation Stabilization Evidence"]
F["ALS Biophysical Therapy<br/>Condensate-Targeted Drug Discovery"]
A --> B
B --> C
C --> D
D --> E
E --> F
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style F fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9aNo linked papers recorded for this hypothesis yet.
No curated PDB or AlphaFold mapping for RNA yet. Search RCSB →
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for RNA.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No resource usage or linked notebooks recorded for this hypothesis yet.